J&J dropped the news yesterday that they’re looking into selling off DePuy Synthes. Honestly, we’ve been calling this move ever since the spin-off wrapped up. But here’s what everyone in the industry is really wondering about: Who could realistically buy an asset of this size and complexity?
A rare… and complicated opportunity
DePuy Synthes remains one of the leading orthopedic players globally, with broad exposure across large joints, trauma, extremities, spine, and sports medicine. With estimated annual revenues around the $9 billion range, this would easily be one of the biggest MedTech deals we’ve seen. A $20 billion acquisition is not just another strategic decision.
So scale is both the attraction and the obstacle.
Private Equity: the quiet frontrunner
Despite the attention around potential strategic buyers, private equity firms may ultimately be the most credible bidders. Here’s why I think PE makes the most sense:
- Money talks: The big PE shops have deep enough pockets to actually make this work without the same antitrust exposure faced by strategics.
- Carve-out experience: DePuy would likely require a complex separation from J&J’s systems. PE firms have gotten really good at untangling these messy corporate separations.
- Portfolio flexibility: PE ownership allows for future divestitures by segment, for example separating spine, trauma, or joints over time.
My bet? We’ll probably see a group of the usual suspects team up that includes firms such as Blackstone, KKR, Carlyle, or similar players.
Strategic Buyers: Logical but Constrained
1.-Zimmer Biomet: Everyone keeps bringing up Zimmer Biomet since they’re already big in orthopedics.
What would it gain?
- Immediate scale in hips and knees
- Commercial synergies
- Expanded global footprint
Key limitations
- Significant antitrust risk in large joints
- Merging two big companies is always a nightmare
- Potential balance sheet pressure
Sure, it makes business sense, but the regulators would probably have a field day with this one, particularly in the U.S. and Europe.
Bottom line: could happen, but it won’t be easy.
2.- Globus Medical: They’ve been crushing it in spine, especially since they brought NuVasive into the fold. Looks good on paper – branching out into ortho makes sense.But here’s the thing – it’s not that simple.
Key challenges:
- Transaction size relative to Globus’ market capitalization
- Ongoing focus on post-NuVasive integration
- Financing complexity at the $20 billion level
They’d probably need to team up with other buyers or just cherry-pick certain assets – a full takeover seems like a long shot.
Bottom line: I don’t see a complete acquisition happening but rather selected asset deals. I wouldn’t take my eyes off it.
Other Strategic Possibilities
- Smith+Nephew: It makes sense strategically – they’d get real scale in orthopedics, but I’m not sure they have the cash or can pull it off.
- Stryker: They’d be a natural fit operationally, but regulators would probably have a field day with this one, especially in core joint segments. In addition, following the recent divestiture of its spine business, hard to explain why they’d jump back into spine with such a big deal from J&J.
- Medtronic: They’ll probably cherry-pick what they want, for example in spine or enabling technologies, rather than pursue the full platform. But I do not see them pursuing even a partial acquisition.
The Break-Up Scenario
There’s this scenario I’ve been thinking about – what if they break up the company instead of just selling it to one buyer?
Under this model:
- Private equity acquires the platform
- They’d clean up each division, cut the fat
- Then they could flip certain pieces to companies that actually want them
This way, they’d probably face fewer regulatory headaches and make way more money in the long run.I mean, we’ve seen this playbook before with other big orthopedic companies. Nine times out of ten, you get more value selling the parts than the whole thing.
What Happens Next
Right now, it looks like J&J is just kicking the tires rather than actually putting DePuy up for sale. The things I’m watching for are when they start the formal breakup process, which banks they hire, PE groups starting to circle, and how the big strategics position themselves with regulators.
Timing will also matter, as these big medtech deals nowadays depend just as much on what regulators will allow as whether they actually make business sense.
The potential sale of DePuy Synthes would represent a defining moment for the orthopedic sector. While strategic buyers such as Zimmer Biomet or others may look logical on the surface, the combination of transaction size, regulatory scrutiny, and carve-out complexity makes private equity the most structurally credible buyer at this stage. That said, in MedTech, what everyone thinks will happen at the start almost never matches how things actually play out.
The real story may ultimately be not who buys DePuy Synthes, but how the asset is reshaped after the transaction.
###